Vetr Inc. recorded Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), raising its target price to $47.90 today
- Updated: January 11, 2017
Vetr Inc. increased the stock price target of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $47.90 indicating a possible upside of 0.08%.
Previously on 1/11/2017, Vetr Inc. released a statement about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) increased the target price from $0.00 to $46.27 that suggested an upside of 0.05%.
Showing a price of $44.16, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) traded -7.74% lower on the day. The last stock price is down -26.10% from the 200-day moving average, compared to the S&P 500 which has decreased -0.05% over the same period. ALNY has recorded a 50-day average of $42.52 and a two hundred day average of $55.82. Volume of trade was down over the average, with 0 shares of ALNY changing hands under the typical 1,579,740
See Chart Below
With a market capitalization of $0, Alnylam Pharmaceuticals, Inc. has 52 week low of $31.38 and a one year high of $88.11 .
A total of 11 equity analysts have released a ratings update on ALNY. 3 brokers rating the stock a strong buy, 8 firms rating the stock a buy, 2 firms rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokers rating the stock a sell with a average stock price target of $117.09.
General Information About Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its investigational RNAi therapeutics focus on Strategic Therapeutic Areas (STArs), including Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases. Its Genetic medicines include Patisiran (ALN-TTR02) and Fitusiran (ALN-AT3), and additional genetic programs, including ALN-AAT.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.